Bendamustine, Rituximab and High Dose Cytarabine
(BR/CR) 2.) Bendamustine, Rituximab, High Dose
Cytarabine and Acalabrutinib (BR/CR-A), and 3.)
Bendamustine, Rituximab and Acalabrutinib (BR-A) in
The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have newly diagnosed Mantle Cell Lymphoma (MCL). If you enroll in this study you will be put on 1 of 3 combination of drugs. The purpose of this study is to find out if one of the three drug combinations is better or worse than the usual approach for your MCL.
If you decide to take part in this study, you will receive one of the following drug combinations for six cycles with a cycle length of 28 days for a total of 6 months of treatment or until your disease gets worse or the side effects become too severe:
1. bendamustine, rituximab, and high dose cytarabine (BR/CR)
2. bendamustine, rituximab, high dose cytarabine, and acalabrutinib (BR/CR-A)
3. bendamustine, rituximab and acalabrutinib (BR-A)
After you finish your study treatment, your doctor will continue to follow your condition for 10 years and watch you for side effects. You will see your doctor every 3 months for 3 years, and then every 6 months until the end of the 10 year period.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to your or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04115631